Description
Moxifloxacin F.C Tablets are presented as forms that containing 400 mg of moxifloxacin (as hydrochloride).
10 Tablet per blister pack. 1 blister with a leaflet in a box.
Category
Antibacterial
Dosage and Administration
Usual adult dose :
– bacterial exacerbations bronchihis : oral , 400 mg once a day for 5 days .
– Community – acquired pneumonia : oral, 400 mg once a day for 7 to 14 days.
– acute sinusitis : oral , 400 mg once a day for 10 days .
– skin and soft tissue infections :
Uncompli cated skin and skin structure infections : oral , 400 mg once a day for 7 days .
Complicated skin and skin stracture infections : oral, 400 mg once a day for 7 to 21 days.
– Complicated intra – abdominal infections : oral, 400 mg once a day for 5 to 14 days.
Usual pediatric dose
Children up to 18 years of age : the safety and effectiveness of moxifloxacin have not been established.
Pregnancy and breast feeding
Pregnancy : Adequate and well – controlled studies in pregnant woman have not been done. FDA pregnancy category C.
Breast feeding : it is kilown whether moxifloxacin is distributed into human milk, however it can be presumed that some will be present.
Side effect
Those indicating need for medical attention
– Incidence unknown : hypersensitivity reactions
Those indicating need for medical attention only if they continue or are bothersome
– Incidence more frequent : conjunctivitis; decreased visual acuity; dry eye; keratitis; ocular discomfort; ocular hyperemia; ocular pain; ocular pruritus; subconjunctival hemorrhage; tearing.
– Incidence less frequent : fever; increased cough; infection; otitis media; pharyngitis; rash; rhinitis.
Precautions
– Checking with physician if no improvement of symptoms within a few days.
– Avoiding concurrent use of antacid, sucralfate and fluroquinolones.
– Taking antacids, didanosine or sucralfate at least 4 hours before or 8 hours after administration.
– Avoiding concurrent use of class IA and class III antiarrhythmic agents.
– Avoiding exposure to direct or undirect sunlight and to artificial ultra violet light during treatment and for 5 days after treatment.
– Discontinuing medication at the first sign or symptom of phototoxicity, such as blistering, itching, rash, or redness of skin, sensation of skin burning or swelling.
– if photo toxicity has occurred, avoiding further sunlight and artificial light until the photoxicity reaction has been resolved, or for 5 days, whichever is longer.
– Caution if dizziness, light headedness, drowsiness occurs.
– Discontinuing medicine and notifying physician if pain, inflammation or rupture of tendon is experienced, resting and refraining from exercise until the diagnosis of tendonitis or tendon rupture has been excluded, or observed symptoms of peripheral neuropathies including pain, burning, tingling, numbness or weakness develop.
– Discontinuing medicine and notifying physician if a diabetic patient has a hypoglycemic episode while being treated with moxifloxacin and insulin or an oral hypoglycemic agent .
Drug interaction
Aminophylline; oxtriphylline; Amiodarone; Tricyclic Antidepressant; Astemizole; Bepredil; Cisapride; Disopyramide; Erythromycin; Pentamidine; Phenothiazines; Procainamide; Quinidine; Sotalol; Terfenadine; Antacids, Aluminum, Calcium, Magnesium Containing; Zinc; Sucrulfate; Anticonvulsant Especially Hydantoin; Phenytoin; Nonesteroidal; Anti-inflammatory drugs (NSAIDS); Didanosine; Didanosine (videx®) Products including : chewable, buffered tablets or pediatric power for oral solution; ferrous sulfate; laxatives, magnesium containing
Storage
Store below 30 ˚c , protect from light and moisture out of reach of children.
Manufactured by pursina pharmaceutical company
Tehran – Iran.
